Rare disease biotech Glycomine raises $12M, with help from Chiesi venture arm

In its Series A announced today Glycomine, an early-stage biotech working on replacement therapies for rare diseases, raised $12 million with help from Sanderling Ventures and Chiesi Ventures.

The round also saw money injected from “existing high net worth individuals,” as well as patients.

Glycomine said in a statement that it will use the cash to finish off IND-enabling preclinical tests and kick-start clinical studies of its substrate replacement therapy in patients with congenital disorder of glycosylation type Ia (CDG-Ia), as well as to speed up discovery efforts towards an enzyme replacement therapy for N-glycanase deficiency (Ngly1).

Webinar

CIOs’ Perspectives: Driving Clinical Trial Innovation with a Unified Platform

IT is being challenged with either trying to fix and maintain an already complex system of solution integrations, or exploring driving business impact by unifying its systems under one platform. Attend and learn about the IT benefits to shifting resources away from disparate systems and moving towards a unified platform.

This disease, an inherited metabolic disorder, is terminal in around 20% of young children, with death usually coming due to infection, liver problems, or heart disease. It’s caused by a deficiency of an enzyme called phosphomannomutase 2.

“Glycomine's approach to a new generation of replacement therapies focuses on intracellular delivery and targeting of treatments to clinically relevant organs,” said Agnes Rafalko, the San Francisco-based biotech’s CEO.

“We are very grateful for the funding and support we have received from our investors, patients’ families, and doctors as we embark on the development of the first-ever replacement therapy for CDG-Ia.”

As is typical in these early raises, Peter McWilliams from Sanderling Ventures and Giacomo Chiesi, managing partner at Chiesi Ventures, have both been given a seat on the biotech’s board.

Suggested Articles

Researchers are studying the retrovirus KoRV-A, which is spreading among koalas, to gain new insights into how DNA evolves.

The FDA approved its first rapid in vitro diagnostic for confirming Ebola virus infections with potential results in about a half-hour.

Shionogi and Hsiri Therapeutics first joined forces last year in a licensing and R&D deal focused on tuberculosis and non-tuberculous lung infections.